Broderick Brian C continued to hold its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 144,476 shares of the biotechnology company’s stock at the end of the second quarter. Broderick Brian C owned approximately 0.10% of Ironwood Pharmaceuticals worth $2,728,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. bought a new stake in Ironwood Pharmaceuticals during the fourth quarter worth about $436,000. AQR Capital Management LLC increased its stake in Ironwood Pharmaceuticals by 15.1% in the fourth quarter. AQR Capital Management LLC now owns 46,418 shares of the biotechnology company’s stock valued at $710,000 after buying an additional 6,075 shares in the last quarter. Norges Bank acquired a new stake in Ironwood Pharmaceuticals during the fourth quarter valued at $18,285,000. Teachers Advisors LLC increased its stake in Ironwood Pharmaceuticals by 0.8% in the fourth quarter. Teachers Advisors LLC now owns 225,596 shares of the biotechnology company’s stock valued at $3,449,000 after buying an additional 1,859 shares in the last quarter. Finally, Parametrica Management Ltd acquired a new stake in Ironwood Pharmaceuticals during the first quarter valued at $258,000. 97.85% of the stock is owned by institutional investors.
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) remained flat at $14.50 during trading on Friday. 1,294,448 shares of the stock traded hands. The company has a 50 day moving average price of $17.19 and a 200-day moving average price of $17.15. The company’s market cap is $2.17 billion. Ironwood Pharmaceuticals, Inc. has a 12 month low of $12.48 and a 12 month high of $19.94.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by $0.05. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The company had revenue of $65.10 million for the quarter, compared to the consensus estimate of $70 million. During the same quarter in the previous year, the business earned ($0.16) EPS. The company’s quarterly revenue was up 19.7% compared to the same quarter last year. On average, equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post ($1.10) EPS for the current fiscal year.
Several analysts have weighed in on the stock. BidaskClub raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Mizuho boosted their price target on shares of Ironwood Pharmaceuticals from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Wedbush reissued a “neutral” rating and issued a $13.00 price target on shares of Ironwood Pharmaceuticals in a research note on Friday, June 16th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $18.50.
In related news, insider Halley E. Gilbert sold 35,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the sale, the insider now owns 35,000 shares in the company, valued at approximately $691,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 7.63% of the company’s stock.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.